| CAS NO: | 59338-87-3 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 2g | 电议 |
| Molecular Weight (MW) | 351.83 |
|---|---|
| Formula | C16H21N5O2.HCl |
| CAS No. | 59338-87-3 (Alizapride HCl); |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 42 mg/mL (119.4 mM) |
| Water: 70 mg/mL (198.95 mM) | |
| Ethanol: <1 mg/mL | |
| Other info | Chemical Name: 6-Methoxy-N-[[1-(2-propenyl)-2-pyrrolidinyl]methyl]-1H-benzotriazole-5-carboxamide Hydrochloride InChi Key: BRECEDGYMYXGNF-UHFFFAOYSA-N InChi Code: InChI=1S/C16H21N5O2.ClH/c1-3-6-21-7-4-5-11(21)10-17-16(22)12-8-13-14(19-20-18-13)9-15(12)23-2;/h3,8-9,11H,1,4-7,10H2,2H3,(H,17,22)(H,18,19,20);1H SMILES Code: O=C(C1=C(OC)C=C(NN=N2)C2=C1)NCC3N(CC=C)CCC3.[H]Cl |
| Synonyms | MS 5080; MS5080; Limican; Plitican; Vergentan; Superan; Alizaprida; Litican; MS-5080 |
| In Vitro | In vitro activity: Alizapride has a N-allyl moiety which potentially could undergo N-deallylation and/or epoxidation reactions, the formation of chemically reactive metabolites can be expected. Kinase Assay: Alizapride hydrochloride is a dopamine receptor antagonist with prokinetic and antiemetic effects which can also be used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. |
|---|---|
| In Vivo | Alizapride demonstrates little toxicity (particularly after parenteral administration) in mice and rats. Alizapride is mainly excreted as unmodified drug after oral or parenteral administration; however, a share of about 25% undergoes metabolic transformation before deletion. Alizapride (5 mg/kg, s.c.) antagonizes the decrease in gastrointestinal transit induced by the above doses of Apomorphine in the rat. |
| Animal model | Mice and rats |
| Formulation & Dosage | 5 mg/kg, s.c. |
| References | J Mass Spectrom. 2012 Jun;47(6):737-50; Pharmacol Res. 1993 May-Jun;27(4):335-47. |
m.cnreagent.com